Designing Novel Hydrazinecarbothioamides as Potential HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Hong Yin; Zheng-Yong Wan; Ge Meng; Fen‐Er Chen; De Clercq Erik; and Christophe Pannecouque

doi:10.3390/proceedings1060274

Related publications

Article2017

Discovery of Biphenyl-Substituted Diarylpyrimidines as New Non-Nucleoside HIV-1 Reverse Transcripttase Inhibitors

Kaijun Jin, Ge Meng, Fen‐Er Chen, De Clercq Erik, Christophe Pannecouque

Article2022

Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase

Kathleen M. Frey, Nicole Bertoletti, Albert H. Chan, Joseph A. Ippolito, Mariela Bollini, Krasimir A. Spasov, William L. Jorgensen, Karen S. Anderson

Frontiers in Molecular Biosciences

Article2025

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles

Zhao Wang, Shawn Rumrill, Dongwei Kang, Samuel Desta Guma, Da Feng, De Clercq Erik, Christophe Pannecouque, Chin‐Ho Chen, Eddy Arnold, Francesc X. Ruiz, Xinyong Liu, Peng Zhan

Article2022

Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region

Tao Zhang, Zhongxia Zhou, Fabao Zhao, Zihao Sang, De Clercq Erik, Christophe Pannecouque, Dongwei Kang, Peng Zhan, Xinyong Liu

Article2023

Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase

Giavana R. Prucha, Sean Henry, Klarissa Hollander, Zachary J. Carter, Krasimir A. Spasov, William L. Jorgensen, Karen S. Anderson

European Journal of Medicinal Chemistry